LONGEVERON INC

Explore Longeveron’s reverse split, CFO RSU grant, and their impact on investor sentiment and future clinical‑development strategy.

Insider buying spikes at Longeveron reveal executive confidence in aging‑therapy pipeline—key insight for investors on potential funding and partnership prospects.

Insider buys and sells at Longeveron (LGVN) reveal CEO confidence and short‑term liquidity moves—investors should focus on the clinical pipeline, not just share trades.

Explore Longeveron’s Phase IIb SASP modulator LNG‑01 and NLRP3 inhibitor LNG‑02, their safety data, FDA Fast‑Track status, and insider equity signals for investors.

Lehr Paul T’s recent Longeveron sale signals a subtle insider shift—investors should weigh this conservative move against the company’s speculative profile and upcoming catalysts.

Insightful analysis of Longeveron’s insider sell‑off reveals how early‑stage biopharma companies balance capital strategy, market access, and drug‑development feasibility to drive investor confidence.

CEO buy‑back at Longeveron: 200k Class A shares purchased, 105k sold—boosting his stake by 147 % amid rising social‑media buzz and $16 m private placement, but clinical milestones remain key to long‑term value.